Advertisement

Health Programmes in Low- and Middle-Income Countries

  • Maria Pallayova
  • Gopesh K. Modi
  • Indranil DasguptaEmail author
Chapter

Abstract

Increase in global population, improvements in cardiovascular survival and aging of the world population are some of the most remarkable global epidemiological changes occurring over the past 30 years. Concurrently, the prevalence and associated clinical and economic burden of diabetic kidney disease have risen worldwide, with the fastest growth occurring in low- and middle-income countries. Limited access to publicly available medical services, health insurance, specialist care, diagnostic tests and antidiabetic and other medications remains a significant challenge in healthcare in low- and middle-income countries.

In this chapter, we discuss how the population and epidemiological developments have influenced diabetic kidney disease programmes centred around chronic kidney disease (CKD) and may impact its future management across different populations and clinical settings in low- to middle-income countries. We also review the current health programmes in low- to middle-income countries and discuss multifactorial approaches based on collaborative efforts to optimize future management of diabetic kidney disease and associated cardio-metabolic risk factors with a view to reducing their sequelae.

Keywords

Diabetes mellitus Chronic kidney disease Low- and middle-income countries Health programmes 

References

  1. 1.
    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):405–12.CrossRefGoogle Scholar
  2. 2.
    Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States renal data system. J Am Soc Nephrol: JASN. 2007;18(10):2644–8.CrossRefGoogle Scholar
  3. 3.
    USRDS. USRDS 1999 annual report: NIH, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.Google Scholar
  4. 4.
    Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608–17.CrossRefGoogle Scholar
  5. 5.
    Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato study. Diabetes Care. 2003;26(7):2150–5.CrossRefGoogle Scholar
  6. 6.
    Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79–83.PubMedGoogle Scholar
  7. 7.
    Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017;60:2129.CrossRefGoogle Scholar
  8. 8.
    Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388(10053):1545–602.Google Scholar
  9. 9.
    Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet (London, England). 2013;382(9888):260–72.CrossRefGoogle Scholar
  10. 10.
    Luther S, Schmitz P. Global epidemiological developments. In: Value creation in the pharmaceutical industry: Wiley-VCH Verlag GmbH & Co. KGaA; 2016. p. 10–43.Google Scholar
  11. 11.
    Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81.CrossRefGoogle Scholar
  12. 12.
    Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47.Google Scholar
  13. 13.
    Organization WH. Global status report on noncommunicable diseases 2014. 2014 ISBN 978 92 4 156485 4.Google Scholar
  14. 14.
    Monteiro CA, Conde WL, Lu B, Popkin BM. Obesity and inequities in health in the developing world. Int J Obesity Relat Metab Disord: J Int Assoc Study Obesity. 2004;28(9):1181–6.CrossRefGoogle Scholar
  15. 15.
    Organization WH. Preventing CHRONIC DISEASES a vital investment. 2005 ISBN 92 4 159359 8.Google Scholar
  16. 16.
    Group TWB. The World Bank Atlas method – detailed methodology [October 09, 2017]. Available from: https://datahelpdesk.worldbank.org/knowldgebase/articles/378832-what-is-the-world-bank-atlas-method.
  17. 17.
    Group TWB. World Bank Country and Lending Groups [October 9, 2017]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
  18. 18.
    ChartsBin statistics collector team 2016, Country Income Groups (World Bank Classification) [17th July, 2017]. Available from: chartsbin.com/view/2438.
  19. 19.
    Fund UUNP. World population dashboard [October 7, 2017]. Available from: https://www.unfpa.org/data/world-population-dashboard.
  20. 20.
    IDF. International Diabetes Federation (IDF) Diabetes Atlas. 7th ed. Brussels; 2015.Google Scholar
  21. 21.
    Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, et al. Assessment of global kidney health care status. JAMA. 2017;317(18):1864–81.CrossRefGoogle Scholar
  22. 22.
    Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88(5):950–7.CrossRefGoogle Scholar
  23. 23.
    Caplin B, Jakobsson K, Glaser J, Nitsch D, Jha V, Singh A, et al. International collaboration for the epidemiology of eGFR in low and middle income populations – rationale and core protocol for the disadvantaged populations eGFR epidemiology study (DEGREE). BMC Nephrol. 2017;18(1):1.CrossRefGoogle Scholar
  24. 24.
    Luyckx VA. Nephrotoxicity of alternative medicine practice. Adv Chronic Kidney Dis. 2012;19(3):129–41.CrossRefGoogle Scholar
  25. 25.
    Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet.Google Scholar
  26. 26.
    Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis: Off J Nat Kidney Found. 2015;66(1 Suppl 1):Svii. S1–305Google Scholar
  27. 27.
    Registry A. 37th Report. Chapter 1: incidence of end stage kidney disease. Australia and New Zealand dialysis and transplant registry. Australia: Adelaide; 2015. p. 2015.Google Scholar
  28. 28.
    Registry E-E. ERA-EDTA registry annual report 2013. Amsterdam: Academic Medical Center, Department of Medical Informatics; 2015. p. 2015.Google Scholar
  29. 29.
    Hossain MP, Goyder EC, Rigby JE, El Nahas MCKD. Poverty: a growing global challenge. Am J Kidney Dis: Off J Nat Kidney Found. 2009;53(1):166–74.CrossRefGoogle Scholar
  30. 30.
    Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118(3):c269–77.CrossRefGoogle Scholar
  31. 31.
    System USRD. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012; 2012.Google Scholar
  32. 32.
    A Health care expenditure on chronic kidney disease in Australia 2004–05. Cat. no. PHE 117. Canberra: AIHW; 2009.Google Scholar
  33. 33.
    Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant: Off Publ Eur Dialysis Trans Assoc – Eur Renal Assoc. 2012;27(Suppl 3):iii73–80.CrossRefGoogle Scholar
  34. 34.
    Tantivess S, Werayingyong P, Chuengsaman P, Teerawattananon Y. Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. BMJ (Clinical research ed). 2013;f462:346.Google Scholar
  35. 35.
    Gadola L, Orihuela L, Perez D, Gomez T, Sola L, Chifflet L, et al. Peritonitis in peritoneal dialysis patients in Uruguay. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2008;28(3):232–5.Google Scholar
  36. 36.
    Sesso R, da Silva CB, Kowalski SC, Manfredi SR, Canziani ME, Draibe SA, et al. Dialysis care, cardiovascular disease, and costs in end-stage renal disease in Brazil. Int J Technol Assess Health Care. 2007;23(1):126–30.CrossRefGoogle Scholar
  37. 37.
    Mahmoud KM, Sheashaa HA, Gheith OA, Wafa EW, Agroudy AE, Sabry AA, et al. Continuous ambulatory peritoneal dialysis in Egypt: progression despite handicaps. Peritoneal Dialysis Int: J Int Soc Peritoneal Dialysis. 2010;30(3):269–73.CrossRefGoogle Scholar
  38. 38.
    Ramachandran R, Jha V. Kidney transplantation is associated with catastrophic out of pocket expenditure in India. PLoS One. 2013;8(7):e67812.CrossRefGoogle Scholar
  39. 39.
    Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet (London, England). 2016;387(10013):61–9.CrossRefGoogle Scholar
  40. 40.
    Barcelo A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Org. 2003;81(1):19–27.PubMedGoogle Scholar
  41. 41.
    Naicker S, Eastwood JB, Plange-Rhule J, Tutt RC. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol. 2010;74(Suppl 1):S129–33.PubMedGoogle Scholar
  42. 42.
    Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet (London, England). 2015;385(9981):1975–82.CrossRefGoogle Scholar
  43. 43.
    Chugh KS, Jha V, Chugh S. Economics of dialysis and renal transplantation in the developing world. Transplant Proc. 1999;31(8):3275–7.CrossRefGoogle Scholar
  44. 44.
    Ayodele OE, Alebiosu CO. Burden of chronic kidney disease: an international perspective. Adv Chronic Kidney Dis. 2010;17(3):215–24.CrossRefGoogle Scholar
  45. 45.
    Zhang L, Wang H. Chronic kidney disease epidemic: cost and health care implications in China. Semin Nephrol. 2009;29(5):483–6.CrossRefGoogle Scholar
  46. 46.
    Jha V. Current status of chronic kidney disease care in Southeast Asia. Semin Nephrol. 2009;29(5):487–96.CrossRefGoogle Scholar
  47. 47.
    National Health Mission MoHFW, Government of India. NHM Guidelines 2017. Available from: http://nhm.gov.in/nrhm-updates/511-guidelines.html.
  48. 48.
    Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton, Vic). 2010;15(Suppl 2):3–9.CrossRefGoogle Scholar
  49. 49.
    Almaguer M, Herrera R, Alfonso J, Magrans C, Manalich R, Martinez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int Suppl. 2005;97:S4–10.CrossRefGoogle Scholar
  50. 50.
    Subsecretaría de Innovación y Calidad. Secretaría de Salud J. Red estrategica de servicios de salud contra la enfermedad renal crónica en Mexico. 2010.Google Scholar
  51. 51.
    Schwedt E, Sola L, Rios PG, Mazzuchi N. Improving the management of chronic kidney disease in Uruguay: a National Renal Healthcare Program. Nephron Clin Pract. 2010;114(1):c47–59.CrossRefGoogle Scholar
  52. 52.
    Md S. Estrategia Nacional de Salud para el cumplimiento de los objetivos sanitarios de la decada 2011–2020. Gobierno de Chile: Santiago; 2011.Google Scholar
  53. 53.
    Mazzuchi N, Schwedt E, Sola L, Gonzalez C, Ferreiro A. Risk factors and prevention of end stage renal disease in Uruguay. Ren Fail. 2006;28(8):617–25.CrossRefGoogle Scholar
  54. 54.
    Stanifer JW, Turner EL, Egger JR, Thielman N, Karia F, Maro V, et al. Knowledge, attitudes, and practices associated with chronic kidney disease in northern Tanzania: a community-based study. PLoS One. 2016;11(6):e0156336.CrossRefGoogle Scholar
  55. 55.
    Liu Q, Li Z, Wang H, Chen X, Dong X, Mao H, et al. High prevalence and associated risk factors for impaired renal function and urinary abnormalities in a rural adult population from southern China. PLoS One. 2012;7(10):e47100.CrossRefGoogle Scholar
  56. 56.
    Vassalotti JA, Li S, McCullough PA, Bakris GL. Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010;30(1):66–73.CrossRefGoogle Scholar
  57. 57.
    Minutolo R, De Nicola L, Mazzaglia G, Postorino M, Cricelli C, Mantovani LG, et al. Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy. Am J Kidney Dis: Off J Nat Kidney Found. 2008;52(3):444–53.CrossRefGoogle Scholar
  58. 58.
    Sharif MU, Elsayed ME, Stack AG. The global nephrology workforce: emerging threats and potential solutions! Clin Kidney J. 2016;9(1):11–22.CrossRefGoogle Scholar
  59. 59.
    Jeet G, Thakur JS, Prinja S, Singh M. Community health workers for non-communicable diseases prevention and control in developing countries: evidence and implications. PLoS One. 2017;12(7):e0180640.CrossRefGoogle Scholar
  60. 60.
    Richards N, Harris K, Whitfield M, O'Donoghue D, Lewis R, Mansell M, et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant: Off Publ Eur Dialysis Transp Assoc – Eur Renal Assoc. 2008;23(2):549–55.CrossRefGoogle Scholar
  61. 61.
    Blickem C, Blakeman T, Kennedy A, Bower P, Reeves D, Gardner C, et al. The clinical and cost-effectiveness of the BRinging information and guided help together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled trial. Trials. 2013;14:28.CrossRefGoogle Scholar
  62. 62.
    Lewis T, Synowiec C, Lagomarsino G, Schweitzer J. E-health in low- and middle-income countries: findings from the center for health market innovations. Bull World Health Organ. 2012;90(5):332–40.CrossRefGoogle Scholar
  63. 63.
    Innovations CfHM. Nacer 2017. Available from: http://healthmarketinnovations.org/program/nacer.
  64. 64.
    Dukpa W, Teerawattananon Y, Rattanavipapong W, Srinonprasert V, Tongsri W, Kingkaew P, et al. Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a package of essential non-communicable disease interventions in Bhutan. Health Policy Plan. 2015;30(8):1032–43.CrossRefGoogle Scholar
  65. 65.
    Geneva WHO. Making choices in health: WHO guide to cost-effectiveness analysis. 2003 ISBN 92 4 154601 8.Google Scholar
  66. 66.
    Marc Suhrcke RAN, David Stuckler, Lorenzo Rocco. Chronic Disease: An Economic Perspective. London: 2006 ISBN 0-9554018-1-X.Google Scholar
  67. 67.
    Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet (London, England). 2017;390:1888.CrossRefGoogle Scholar
  68. 68.
    Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant: Off Publ Eur Dialysis Transp Assoc – Eur Renal Assoc. 2009;24(5):1355–8.CrossRefGoogle Scholar
  69. 69.
    Mills A. Health care systems in low- and middle-income countries. N Engl J Med. 2014;370(6):552–7.CrossRefGoogle Scholar
  70. 70.
    MSCaS P. Health programs in a developing country – why do we fail? Health Syst Policy Res. 2016;3(3):27.Google Scholar
  71. 71.
    Depine S. The role of government and competing priorities in minority populations and developing nations. Ethn Dis. 2009;19(1 Suppl 1):S1-73-9.PubMedGoogle Scholar
  72. 72.
    Okpechi IG, Bello AK, Ameh OI, Swanepoel CR. Integration of Care in Management of CKD in resource-limited settings. Semin Nephrol. 2017;37(3):260–72.CrossRefGoogle Scholar
  73. 73.
    Nations U. Sustainable development goals – goal 3: ensure healthy lives and promote Well-being for all at all ages [July 27, 2017]. Available from: http://www.un.org/sustainabledevelopment/health/.
  74. 74.
    Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87(3):502–28.CrossRefGoogle Scholar
  75. 75.
    Kidney disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;4:1–335.Google Scholar
  76. 76.
    Kidney Disease. Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009:S1–130.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Maria Pallayova
    • 1
    • 2
  • Gopesh K. Modi
    • 3
  • Indranil Dasgupta
    • 4
    • 5
    Email author
  1. 1.Department of Medicine and Clinical Research CoreWeill Cornell Medicine in Qatar and New YorkNew YorkUSA
  2. 2.Department of Human PhysiologyPavol Jozef Safarik University Faculty of MedicineKosiceSlovak Republic
  3. 3.Samarpan-Noble Kidney CenterBhopalIndia
  4. 4.Renal UnitHeartlands HospitalBirminghamUK
  5. 5.University of BirminghamBirminghamUK

Personalised recommendations